BioNTech (NASDAQ:BNTX) Trading Down 0.2% – Here’s What Happened

BioNTech SE (NASDAQ:BNTX) traded down 0.2% during trading on Tuesday . The stock traded as low as $116.64 and last traded at $116.98. 130,907 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 811,973 shares. The stock had previously closed at $117.20.

Wall Street Analysts Forecast Growth

BNTX has been the topic of several recent research reports. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. JPMorgan Chase & Co. lowered their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a report on Tuesday, November 26th. Bank of America boosted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, HSBC raised their price target on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Trading Down 0.3 %

The company has a market capitalization of $28.00 billion, a P/E ratio of -56.11 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a fifty day moving average price of $113.89 and a 200-day moving average price of $98.94.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the previous year, the business earned $0.73 earnings per share. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, equities research analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current year.

Institutional Trading of BioNTech

Hedge funds have recently modified their holdings of the business. Vestcor Inc bought a new position in BioNTech in the 3rd quarter valued at approximately $784,000. Y Intercept Hong Kong Ltd purchased a new position in shares of BioNTech during the third quarter valued at about $718,000. XTX Topco Ltd bought a new stake in shares of BioNTech in the 3rd quarter worth about $459,000. State Street Corp raised its stake in shares of BioNTech by 2.0% in the third quarter. State Street Corp now owns 155,867 shares of the company’s stock valued at $18,512,000 after acquiring an additional 3,014 shares during the period. Finally, Redmile Group LLC bought a new position in shares of BioNTech during the third quarter valued at approximately $18,345,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.